Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2013 · 10-Q
Revenue—
Net Income-$1.65M-$1.65MN/M vs Q2 2012 EPS Diluted-$1.86-$1.86N/M vs Q2 2012 Operating Income-$1,655,000N/M Operating Cash Flowderived-$1,448,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Jun 30, 2013 · filed Aug 12, 2013 · 43 d after period end